205 related articles for article (PubMed ID: 33530256)
21. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
22. A case of giant sarcomatoid carcinoma ex-pleomorphic adenoma of the parotid gland.
Hasnaoui M; Masmoudi M; Abdeljelil NB; Belaid T; Mighri K
Pan Afr Med J; 2020; 37():2. PubMed ID: 32983320
[TBL] [Abstract][Full Text] [Related]
23. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
[TBL] [Abstract][Full Text] [Related]
24. Parotid tail pleomorphic adenoma extending to the parapharyngeal space.
Polat K; Doğan M; Yüce S; Uysal IÖ; Müderris S
J Craniofac Surg; 2013 Mar; 24(2):e124-6. PubMed ID: 23524806
[TBL] [Abstract][Full Text] [Related]
25. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
26. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
[TBL] [Abstract][Full Text] [Related]
27. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.
Pollack M; Keating K; Wissinger E; Jackson L; Sarnes E; Cuffel B
Curr Med Res Opin; 2021 Jan; 37(1):59-70. PubMed ID: 33148054
[TBL] [Abstract][Full Text] [Related]
28. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
Ann Oncol; 2019 Nov; 30(Suppl_8):viii31-viii35. PubMed ID: 31738425
[TBL] [Abstract][Full Text] [Related]
29. Intracapsular carcinoma ex-pleomorphic adenoma of the parapharyngeal space: report of two cases and review of the literature.
Accorona R; Barbieri D; Farina D; Lombardi D; Bussi M; Nicolai P
Tumori; 2017 Nov; 103(Suppl. 1):e73-e77. PubMed ID: 29143959
[TBL] [Abstract][Full Text] [Related]
30. Carcinoma ex benign pleomorphic adenoma of the parotid gland.
Nouraei SA; Hope KL; Kelly CG; McLean NR; Soames JV
Plast Reconstr Surg; 2005 Oct; 116(5):1206-13. PubMed ID: 16217459
[TBL] [Abstract][Full Text] [Related]
31. Adenoid cystic carcinoma ex pleomorphic adenoma of the parotid gland.
Ide F; Mishima K; Yamada H; Saito I
Head Neck Pathol; 2009 Jun; 3(2):159-62. PubMed ID: 19644550
[TBL] [Abstract][Full Text] [Related]
32. Metastasizing pleomorphic adenoma in the multiple organs: A case report on FDG-PET/CT imaging.
Koyama M; Terauchi T; Koizumi M; Tanaka H; Sato Y
Medicine (Baltimore); 2018 Jun; 97(23):e11077. PubMed ID: 29879077
[TBL] [Abstract][Full Text] [Related]
33. [Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
Delaye M; Rodrigues M
Bull Cancer; 2020 Nov; 107(11):1085-1086. PubMed ID: 33169692
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Doz F; van Tilburg CM; Geoerger B; Højgaard M; Øra I; Boni V; Capra M; Chisholm J; Chung HC; DuBois SG; Gallego-Melcon S; Gerber NU; Goto H; Grilley-Olson JE; Hansford JR; Hong DS; Italiano A; Kang HJ; Nysom K; Thorwarth A; Stefanowicz J; Tahara M; Ziegler DS; Gavrilovic IT; Norenberg R; Dima L; De La Cuesta E; Laetsch TW; Drilon A; Perreault S
Neuro Oncol; 2022 Jun; 24(6):997-1007. PubMed ID: 34850167
[TBL] [Abstract][Full Text] [Related]
35. Familial mixed tumors of the parotid gland.
Ahn MS; Hayashi GM; Hilsinger RL; Lalwani AK
Head Neck; 1999 Dec; 21(8):772-5. PubMed ID: 10562692
[TBL] [Abstract][Full Text] [Related]
36. Intracapsular carcinoma ex pleomorphic adenoma. Report of a case with unusual metastatic behaviour.
Felix A; Rosa-Santos J; Mendonça ME; Torrinha F; Soares J
Oral Oncol; 2002 Jan; 38(1):107-10. PubMed ID: 11755829
[TBL] [Abstract][Full Text] [Related]
37. Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.
Halalsheh H; McCarville MB; Neel M; Reynolds M; Cox MC; Pappo AS
Pediatr Blood Cancer; 2018 Oct; 65(10):e27271. PubMed ID: 29893456
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
Drilon A; Tan DSW; Lassen UN; Leyvraz S; Liu Y; Patel JD; Rosen L; Solomon B; Norenberg R; Dima L; Brega N; Shen L; Moreno V; Kummar S; Lin JJ
JCO Precis Oncol; 2022 Jan; 6():e2100418. PubMed ID: 35085007
[TBL] [Abstract][Full Text] [Related]
39. Giant parotid pleomorphic adenoma involving the parapharyngeal space: report of a case.
Rodríguez-Ciurana J; Rodado C; Sáez M; Bassas C
J Oral Maxillofac Surg; 2000 Oct; 58(10):1184-7. PubMed ID: 11021720
[No Abstract] [Full Text] [Related]
40. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Waguespack SG; Drilon A; Lin JJ; Brose MS; McDermott R; Almubarak M; Bauman J; Casanova M; Krishnamurthy A; Kummar S; Leyvraz S; Oh DY; Park K; Sohal D; Sherman E; Norenberg R; Silvertown JD; Brega N; Hong DS; Cabanillas ME
Eur J Endocrinol; 2022 Apr; 186(6):631-643. PubMed ID: 35333737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
